
Bio-Rad Laboratories, Inc. (NYSE:BIO) reported better-than-expected second-quarter financial results on Thursday.
Bio-Rad Laboratories reported quarterly earnings of $2.61 per share which beat the analyst consensus estimate of $1.76 per share. The company reported quarterly sales of $651.600 million which beat the analyst consensus estimate of $615.110 million.